It is a perilous time to establish a CDMO operation, says expert
CDMOs are not immune to current market conditions despite a stream of new entries and continued investment, according to industry veteran Roger Lias. This year has seen a surge of contract development manufacturing organizations (CDMOs) enter the Life Sciences space. In June, the Public Investmen ...
Pfizer says its manufacturing and marketing prowess, driven by COVID-era branding, will keep it ahead in a reinvigorated vaccine market.
For v ...
Pfizer will use Ginkgo Bioworks’ RNA technology to discover and develop RNA molecules across three unspecified programs.
Under the terms of ...
Contract development manufacturing organisation (CDMO) WuXi Vaccines has inaugurated a facility in Suzhou acquired from Harbour BioMed last year. ...
Kyverna Therapeutics will implement its Ingenui-T platform into ElevateBio’s cell product manufacturing activities at its BaseCamp, Massachuset ...
Recent Tweets
-
To everyone at #BiotechWeekBoston - thanks for a great event & see you next year!
12 months ago
-
@Dan5tanton hosting BioProcess Insider’s State of the Industry chat at the spotlight theater here at #BWB2022 https://t.co/UBCZCf1Jng
1 year ago
-
@ADaviesDHCG I couldn’t find a seat, it was so busy! A great talk with some really interesting and helpful talks ma… https://t.co/5b3mjes9tb
1 year ago
-
@ADaviesDHCG on stage at the Spotlight Theater discussing CGT capacity & demand #BWB2022 https://t.co/d5T0KYm7mp
1 year ago
